We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Ultra-Portable Rapid Test Platform Offers Complete Sample-to-Answer Solution for Remote and Off-Grid Testing

By LabMedica International staff writers
Posted on 07 Jun 2023
Print article
Image: The Geo portable testing platform integrated with the Snap collection device (Photo courtesy of ReadyGo Diagnostics)
Image: The Geo portable testing platform integrated with the Snap collection device (Photo courtesy of ReadyGo Diagnostics)

An ultra-portable isothermal molecular diagnostics system integrated with a patented device which combines sample collection and processing into a single, easy-to-use disposable is set to revolutionize low-cost decentralized diagnostic testing.

ReadyGo Diagnostics’ (Bath, UK) Geo is a rapid test platform designed for small labs, pharmacies, and remote diagnostic needs. This highly portable device enables molecular tests to be run anywhere and delivers results in approximately 20 minutes. Designed to go anywhere, Geo uses ReadyGo’s Flex reagents which do not require cold-chain, making it a true off-grid, go-anywhere test platform. The platform also does not require a specialized operator or accurate pipetting thanks to its pre-measured reagents.

Combined with ReadyGo's innovative sample collection device, Snap, Geo offers a comprehensive solution for remote and off-grid testing of up to eight samples simultaneously. Snap, a compact, single-use device about the size of a highlighter pen, integrates sample collection and preparation. It uses a specialized material to absorb a specified amount of the patient's sample via capillary action, which is then mixed with a dried lysis reagent stored within the device. The reagent's components are similar to those in mouthwash, safe for human use, and highly effective at breaking down pathogens without inhibiting nucleic acid amplification reactions.

Operating the Snap device is simple: the user collects a sample, and bends the device to break an internal valve, releasing the exact amount of buffer required for the reaction into the chamber. Then, the user simply squeezes the bulb on the end of the device to release the contents for diagnostic testing. This simple sample preparation method also reduces the cost of the diagnostic assay, as it does not require any moving components. Snap eliminates the buffer measuring step, which some users found challenging when using over-the-counter lateral flow COVID-19 tests. When paired with Geo's eight-well isothermal amplification platform, the user can directly transfer Snap's contents into tubes pre-filled with assay reagents, then place the tubes in the Geo instrument for amplification and reading. Snap can be used with various samples, including saliva, nasal, buccal, and even surface samples, with ReadyGo also developing options for blood, urine, and stool sample collection.

ReadyGo has designed tests using recombinase polymerase amplification (RPA) and loop-mediated isothermal amplification (LAMP) for Geo's isothermal amplification and is currently developing its proprietary chemistry. The Geo platform is expected to be priced under USD 1,000, with individual assays costing around USD 10, making it a low-cost diagnostic solution for small labs and research groups. Additionally, the Geo system is designed for 3D printing in its manufacturing process, in line with ReadyGo’s goal to decentralize production and commercialization. This design will allow the system to be produced locally wherever testing is required and also provide the benefit of lower assembly costs in various parts of the world. The Geo system's streamlined design also reduces the need for plastics in its construction. ReadyGo aims to collaborate with other labs and companies, as well as develop tests that can be commercialized by its partners.

Related Links:
ReadyGo Diagnostics 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more

Pathology

view channel
Image: The QIAseq xHYB Mycobacterium tuberculosis Panel uses next-generation sequencing (Photo courtesy of 123RF)

New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance

Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.